200 related articles for article (PubMed ID: 36636407)
1. Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.
Deng H; Liang H; Chen J; Wang W; Li J; Xiong S; Cheng B; Li C; Chen Z; Wang H; Zheng J; Guo Z; He J; Liang W
Transl Lung Cancer Res; 2022 Dec; 11(12):2364-2381. PubMed ID: 36636407
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
J Thorac Cardiovasc Surg; 2024 Feb; ():. PubMed ID: 38342430
[TBL] [Abstract][Full Text] [Related]
4. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
5. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy.
Deng H; Xiong S; Zhong R; Zheng Y; Liang H; Cheng B; Li J; Li F; Chen Z; Wang H; He J; Liang W
Exp Hematol Oncol; 2023 Apr; 12(1):40. PubMed ID: 37072866
[TBL] [Abstract][Full Text] [Related]
6. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
7. Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non-small-cell lung cancer.
Chen J; Ang KL; Wang Z; Lei F; He J; Li S
Thorac Cancer; 2023 May; 14(14):1260-1267. PubMed ID: 37021595
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer.
Zheng J; Li Y; Jin C; Ruan K; Sun K; Chen H; Wang M; Zhang S; Zhou J; Zhou J
Lung Cancer; 2023 Oct; 184():107326. PubMed ID: 37579576
[TBL] [Abstract][Full Text] [Related]
9. Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy.
Sun T; Huang S; Jiang Y; Yuan H; Wu J; Liu C; Zhang X; Tang Y; Ben X; Tang J; Zhou H; Zhang D; Xie L; Chen G; Zhao Y; Wang S; Xu H; Qiao G
Front Bioeng Biotechnol; 2022; 10():1010672. PubMed ID: 36277407
[No Abstract] [Full Text] [Related]
10. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
[TBL] [Abstract][Full Text] [Related]
11. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant immunotherapy combined with chemotherapy in the treatment of stage III lung squamous cell carcinoma: a retrospective cohort study.
Guo J; Lin SD; Minervini F; Geraci TC; Kim JJ; Tong CY; Li XJ; Cao C
J Thorac Dis; 2023 Oct; 15(10):5658-5668. PubMed ID: 37969291
[TBL] [Abstract][Full Text] [Related]
13. Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer.
Dai J; Zhu X; Li D; Huang Y; Liu X; He W; Duan L; Zhao D; Zhu Y; Chen C; Provencio M; Ramirez RA; Antonoff MB; Wu C; Jiang G
Transl Lung Cancer Res; 2022 Feb; 11(2):188-200. PubMed ID: 35280313
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases.
Li X; Xia C; Liu M; Liu J; Dong M; Zhao H; Xu S; Wang D; Wei S; Song Z; Chen G; Liu H; Chen J
Front Oncol; 2022; 12():843116. PubMed ID: 36176413
[TBL] [Abstract][Full Text] [Related]
15. Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer.
Liang H; Yang C; Gonzalez-Rivas D; Zhong Y; He P; Deng H; Liu J; Liang W; He J; Li S
Transl Lung Cancer Res; 2021 Jan; 10(1):143-155. PubMed ID: 33569300
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
Lei J; Zhao J; Gong L; Ni Y; Zhou Y; Tian F; Liu H; Gu Z; Huang L; Lu Q; Wang X; Sun J; Yang E; Wang T; Zhong D; Wang J; Zhao Z; Liu Z; Wang C; Wang X; Lei G; Yan X; Jiang T
JAMA Oncol; 2023 Oct; 9(10):1348-1355. PubMed ID: 37535377
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
Zhai H; Li W; Jiang K; Zhi Y; Yang Z
Cancer Manag Res; 2022; 14():515-524. PubMed ID: 35173485
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
Zheng Y; Feng B; Chen J; You L
Front Immunol; 2023; 14():1273220. PubMed ID: 38106421
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive
Cui Y; Lin Y; Zhao Z; Long H; Zheng L; Lin X
Front Immunol; 2022; 13():994917. PubMed ID: 36466929
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
Hou X; Shi X; Luo J
Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
